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Abstract
Background
Selective outcome reporting of either interesting or positive research findings is problematic,
running the risk of poorly-informed treatment decisions. We aimed to assess the extent of
outcome and other discrepancies and possible selective reporting between registry entries
and published reports among leading medical journals.
Methods
Randomized controlled trials published over a 6-month period from July to December 31st,
2013, were identified in five high impact medical journals: The Lancet, British Medical Jour-
nal, New England Journal of Medicine, Annals of Internal Medicine and Journal of American
Medical Association were obtained. Discrepancies between published studies and registry
entries were identified and related to factors including registration timing, source of funding
and presence of statistically significant results.
Results
Over the 6-month period, 137 RCTs were found. Of these, 18% (n = 25) had discrepancies
related to primary outcomes with the primary outcome changed in 15% (n = 20). Moreover,
differences relating to non-primary outcomes were found in 64% (n = 87) with both omission
of pre-specified non-primary outcomes (39%) and introduction of new non-primary out-
comes (44%) common. No relationship between primary or non-primary outcome change
and registration timing (prospective or retrospective; P = 0.11), source of funding (P = 0.92)
and presence of statistically significant results (P = 0.92) was found.
Conclusions
Discrepancies between registry entries and published articles for primary and non-primary
outcomes were common among trials published in leading medical journals. Novel ap-
proaches are required to address this problem.
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Introduction
The spotlight has been placed on deficient conduct and reporting of research in recent years
[1]. In view of the profound influence of research findings on public health policy, the configu-
ration of services and the delivery of care, these limitations are concerning [2]. The issue of
publication bias, whereby positive or interesting results are more likely to be published and
may be given greater prominence and priority than negative results is a significant problem [3].
Discrepancy between pre-specified and published outcomes and key methodological aspects of
clinical trials is also prevalent and potentially problematic [4]. Inconsistencies between out-
comes, in particular, may lead to biased and misleading results, particularly if these changes are
predicated on the observed trial results. Selective reporting may manifest as preferential publi-
cation of either interesting or positive research findings, while less interesting, often negative,
results are not published or their importance is downgraded. Moreover, only results from cer-
tain time points may be presented [4].
Reporting discrepancies and selective outcome reporting may lead to incorrect inferences,
which in turn may culminate in uninformed and inappropriate treatment choices. The CON-
SORT (Consolidated Standards of Reporting Trials) guidelines are directed at promoting clear
and unbiased reporting of clinical trials [5]. Within these guidelines it has been suggested that
primary and non-primary outcomes should be defined in a clear manner in conjunction with
effect sizes and confidence intervals [5]. Post hoc adjustments and subgroup analyses should be
clear so biased or data-driven changes can be exposed. There is also empirical evidence both of
inconsistencies and selective outcome reporting in both medical and surgical journals with is-
sues exposed both in relation to primary and non-primary outcome reporting [6–11].
Registration of clinical trials has been advocated to introduce greater clarity. Clinical trial
registries can be analysed to look for differences between the original entry study and the final
article. This process can both help to identify selective outcome reporting and to find other in-
consistencies. Mandatory trial registration has been adopted widely with the International
Committee of Medical Journal Editors advocating registration prior to consideration for publi-
cation in a member journal [12]. The World Health Organization (WHO) has subsequently
published a Trial Registration Data Set with 20 core items, including the primary and key non-
primary outcomes [13].
Previous studies have highlighted a higher prevalence of methodological problems among
both randomised controlled trials (RCTs) and systematic reviews within medical journals with
a lower impact factor [14, 15]. With the exception of an analysis of reporting within the Journal
of the American Medical Association and British Medical Journal [16], there is no evidence re-
lating to the prevalence of discrepancies between registry entries and final reports within the
leading medical journals. The aim of this study was to identify the prevalence of discrepancies
between trial registry entries and final reports of RCTs published in leading medical journals
with the highest impact factor. The differences between pre-specified and final outcome mea-
sures were to be determined. Alterations to be considered included addition or omission of out-
come measures, changes from primary to non-primary outcomes or vice versa, and changes in
the definition of outcome measures. Associations between discrepancies and a range of factors
including statistical significance and funding sources was also to be explored.
Materials and Methods
Randomised controlled trials published over a 6-month period from July to December 31st,
2013 were identified in five highest impact medical journals based on Thomson Reuters List
2014 by searching the electronic archives of the following: The Lancet, British Medical Journal
(BMJ), New England Journal of Medicine (NEJM), Annals of Internal Medicine (AIM) and
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Journal of American Medical Association (JAMA). Two authors (PSF, DK) identified RCTs
for inclusion by independent searching of the electronic archives of these journals. Associated
registry entries were identified within the abstract or methods section of the published
manuscript.
Data from eligible studies were extracted independently and entered on pre-piloted stan-
dardized forms. Initial calibration was performed between the two researchers (PSF, DK) on 10
articles. Disagreements were resolved by discussion or, if necessary, with adjudication by a
third researcher (NP). Information obtained included number and type of primary and non-
primary outcomes based on explicit definitions within both the registry entries and the final
publication. Changes in outcomes including addition, removal or redefinition of outcomes
were recorded. An example of definition change would be a registry indicating, in a hypotheti-
cal study of a hypoglycemic agent, that the primary outcome was glycemic control assessed at 1
month, while glycemic control assessed at 2 months was reported in the study. However, if the
registry entry reported the outcome without the time-point and the time-point was added in
the report, this was noted but was not recorded as a discrepancy overall as additional detail is
typical within trial reports.
In addition, data relating to changes to selection criteria, randomization and blinding proce-
dures, analysis (per-protocol or intention-to-treat), and timing of assessments, sample size,
funding, ethics and sponsorship were obtained. Estimates and associated confidence intervals
where available were extracted for the primary outcome. Other characteristics including the trial
register used and whether the research involved a single or multiple centers were also extracted.
Descriptive statistics were calculated for all included studies for the following variables:
journal of publication, number of research centers, significance of the primary outcome, and
registry used. Data were collected in relation to possible discrepancies between registry entries
and final reports both for primary and non-primary outcomes. Other discrepancies in relation
to trial design, randomization procedures, blinding, approach to analysis (intention to treat or
per-protocol), incorporation of subgroup analyses, sample size, funding and registration de-
tails, timing of registration (retrospective or prospective), and allocation ratio were identified.
Cross-tabulations were undertaken to investigate associations between discrepancies and tim-
ing of registration, type of sponsorship, and presence of significant results. All statistical analy-
ses were conducted with STATA version 12.1 software (Stata Corporation, College Station,
Texas, USA).
Results
One hundred and thirty-seven RCTs were identified across the five journals (Fig 1, S1 Table).
The greatest proportion of RCTs were identified in NEJM (n = 47, 34%), followed by Lancet
(n = 32, 23%) and JAMA (n = 31, 22%). The vast majority were undertaken in multiple centers
(n = 124, 91%), with a relatively even spread between significant (n = 67, 49%), and non-signif-
icant primary outcomes (n = 70, 51%). Of the various trial registries clinicaltrials.gov (n = 98,
72%) and controlled-trials.com (n = 25, 18%) were most popular. Most primary outcomes
were dichotomous (n = 91, 66%).
Discrepancies related to primary outcomes were identified in 18% (n = 25) of the RCTs as-
sessed. The definition of the primary outcome had changed in 15% (n = 20). In relation to
non-primary outcomes, differences were found for 64% (n = 87) with similar frequency of both
omission of pre-specified non-primary outcomes (39%) and introduction of new non-primary
outcomes (44%) in published studies. No discrepancies related to either the intervention or de-
sign of the trial were identified. However, inclusion and exclusion criteria were altered in 24%
(n = 33). Randomization procedures and approach to analysis were rarely outlined in the
Outcome Discrepancies in Leading Journals
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registries (96%). Subgroup analyses were described in the final report but not in the registry
commonly (54%, n = 74). Certain discrepancies were found more commonly in individual
journals including changes relating to randomization, blinding, subgroup analyses, funding
and sponsorship (Table 1).
Regarding primary outcomes, no association was found for outcome change (report vs reg-
istry entry) or omission in the final report and registration timing (prospective or retrospective;
P = 0.11), source of funding (P = 0.92) and presence of statistically significant results
(P = 0.92). Similarly, no association was observed for these variables concerning changes in
Fig 1. Flow diagram for article retrieval.
doi:10.1371/journal.pone.0127495.g001
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Table 1. Distribution of discrepancy variables between registration and published report per journal (n = 137).
Variables Journal
AIM BMJ JAMA Lancet NEJM Total p-value
N (%) N (%) N (%) N (%) N (%) N (%)
Signiﬁcance of primary outcome 0.176¼
Non-signiﬁcant 2 (20.0) 12 (70.6) 16 (51.6) 16 (50.0) 24 (51.1) 70 (51.1)
Signiﬁcant 8 (80.0) 5 (29.4) 15 (48.4) 16 (50.0) 23 (48.9) 67 (48.9)
Timing of registration 0.206¼
Prospective 10 (100.0) 15 (88.2) 30 (96.8) 29 (90.6) 38 (80.8) 122 (89.1)
Retrospective 0 (0.0) 2 (11.8) 1 (3.2) 3 (9.4) 9 (19.2) 15 (10.9)
Discrepancy in primary outcome 0.256¼
No 10 (100.0) 11 (64.7) 26 (83.9) 27 (84.4) 38 (80.8) 112 (81.7)
Yes 0 (0.0) 6 (35.3) 5 (16.1) 5 (15.6) 9 (19.2) 25 (18.3)
Discrepancy in non-primary outcome 0.146¼
No 7 (70.0) 7 (41.2) 10 (32.3) 8 (25) 18 (38.3) 50 (36.5)
Yes 3 (30.0) 10 (58.8) 21 (67.7) 24 (75) 29 (61.7) 87 (63.5)
Discrepancy in inclusion criteria 0.276¼
No 10 (100.0) 13 (76.5) 26 (83.9) 22 (68.7) 32 (68.1) 103 (75.2)
Yes 0 (0.0) 4 (23.5) 5 (16.1) 10 (31.3) 14 (29.8) 33 (24.1)
Not reported 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.1) 1 (0.7)
Discrepancy in randomization 0.0056¼
No 0 (0.0) 3 (17.6) 1 (3.2) 5 (15.6) 0 (0.0) 9 (6.6)
Yes 0 (0.0) 3 (17.6) 1 (3.2) 1 (3.1) 1 (2.1) 6 (4.3)
Stated in registry, not in ﬁnal report 0 (0.0) 1 (5.9) 1 (3.2) 0 (0.0) 0 (0.0) 2 (1.5)
Stated in ﬁnal report, not in registry 10 (100.0) 10 (58.9) 26 (83.9) 26 (81.3) 45 (95.8) 117 (85.4)
Stated neither in registry, nor in ﬁnal report 0 (0.0) 0 (0.0) 2 (6.5) 0 (0.0) 1 (2.1) 3 (2.2)
Discrepancy in blinding <0.0016¼
No 9 (90.0) 8 (47.1) 24 (77.4) 20 (62.5) 44 (93.6) 105 (76.6)
Yes 1 (10.0) 1 (5.8) 6 (19.4) 3 (9.4) 0 (0.0) 11 (8.1)
Stated in registry, not in ﬁnal report 0 (0.0) 0 (0.0) 1 (3.2) 0 (0.0) 0 (0.0) 1 (0.7)
Stated in ﬁnal report, not in registry 0 (0.0) 8 (47.1) 0 (0.0) 9 (28.1) 2 (4.3) 19 (13.9)
Stated neither in registry, nor in ﬁnal report 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.1) 1 (0.7)
Discrepancy in population analysis 0.166¼
No 0 (0.0) 1 (5.8) 2 (6.5) 2 (6.3) 0 (0.0) 5 (3.7)
Stated in ﬁnal report, not in registry 8 (80.0) 13 (76.5) 28 (90.3) 29 (90.6) 42 (89.4) 120 (87.6)
Stated neither in registry, nor in ﬁnal report 2 (20.0) 3 (17.7) 1 (3.2) 1 (3.1) 5 (10.6) 12 (8.7)
Discrepancy in outcome time-points 0.076¼
No 10 (0.0) 11 (64.7) 28 (90.3) 27 (84.4) 32 (68.1) 108 (78.8)
Yes 0 (0.0) 6 (35.3) 3 (9.7) 5 (15.6) 13 (27.7) 27 (19.7)
Stated in registry, not in ﬁnal report 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (4.2) 2 (1.5)
Discrepancy in subgroup analysis 0.0056¼
No 0 (0.0) 0 (0.0) 2 (6.5) 1 (3.1) 1 (2.1) 4 (2.9)
Yes 0 (0.0) 4 (23.5) 0 (0.0) 0 (0.0) 0 (0.0) 4 (2.9)
Stated in ﬁnal report, not in registry 4 (40.0) 4 (23.5) 19 (61.3) 16 (50.0) 31 (65.9) 74 (54)
Stated neither in registry, nor in ﬁnal report 6 (60.0) 9 (53.0) 10 (32.2) 15 (46.9) 15 (32) 55 (40.2)
Discrepancy in sample size 0.586¼
No 5 (50.0) 9 (52.9) 16 (51.6) 21 (65.6) 23 (48.9) 74 (54)
Yes 5 (50.0) 8 (47.1) 15 (48.4) 10 (31.3) 24 (51.1) 62 (45.3)
Stated in registry, not in ﬁnal report 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.1) 0 (0.0) 1 (0.7)
(Continued)
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non-primary outcomes or where the primary outcome was omitted from the final publication
(Table 2). An association between change in inclusion criteria and source of funding was noted
with company-sponsored trials more likely to show changes (P = 0.014). No other statistically
significant findings were observed.
Discussion
The presence of inconsistency between clinical trial reports and registry entries has previously
been confirmed in major medical and surgical journals and within drug trials [6–11]. This
study confirms the pattern alluded to in these studies; however, an association between timing
of registration, funding source and presence of significant outcomes and discrepancies relating
to primary and non-primary outcomes was not found. Even in high impact journals, which all
endorse trial registration in guidelines for authors, selective reporting remains problematic. A
previous analysis of selective reporting within JAMA and BMJ highlighted a discrepancy rate
of 19% and 47%, respectively [16]. Analogous rates of discrepancy were exposed in the present
analysis suggesting that merely endorsing and promoting registration is not sufficient; further
action is required to produce more meaningful improvements.
It appears that primary outcomes are being handled with greater fidelity than is the case
with non-primary outcomes. Nevertheless, a sizeable proportion (18%) of studies were exposed
as having discrepancies between primary outcomes on registry entries and in the final report.
While this figure is considerably lower than that identified in a recent review of surgical studies,
where rates of up to 49% were found [9], rates ranging from 18% to 43% have been found in
previous studies [6–8, 10]. This problem stemmed relatively evenly from either omission of pri-
mary outcomes outlined on the registry, de novo introduction of previously unmentioned out-
comes and downgrade of primary to non-primary outcomes. This distribution is in accordance
with other studies reporting the previous two issues with a frequency of 8% to 18% [6, 8] and
the latter at between 4% and 22% [6, 7]. This, therefore, confirms that trials published more re-
cently in the most reputed journals are susceptible to analogous levels of selective reporting as
was revealed up to 5 years ago [6–8].
In keeping with previous findings, the rate of disagreement between non-primary outcomes
listed on registry entries and in final reports was 64%. The same figure was previously
Table 1. (Continued)
Variables Journal
AIM BMJ JAMA Lancet NEJM Total p-value
N (%) N (%) N (%) N (%) N (%) N (%)
Discrepancy in funding 0.0046¼
No 8 (80.0) 15 (88.2) 17 (54.8) 26 (81.3) 44 (93.6) 110 (80.3)
Yes 0 (0.0) 0 (0.0) 2 (6.5) 1 (3.1) 1 (2.1) 4 (2.9)
Stated in ﬁnal report, not in registry 2 (20.0) 2 (11.8) 12 (38.7) 5 (15.6) 2 (4.3) 23 (16.8)
Discrepancy in sponsorship 0.0026¼
No 9 (90.0) 13 (76.5) 23 (74.2) 18 (56.3) 25 (53.2) 88 (64.2)
Yes 0 (0.0) 0 (0.0) 5 (16.1) 1 (3.1) 0 (0.0) 6 (4.4)
Stated in registry, not in ﬁnal report 1 (10.0) 4 (23.5) 3 (9.7) 13 (40.6) 21 (44.7) 42 (30.7)
Stated neither in registry, nor in ﬁnal report 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.1) 1 (0.7)
Total 10 (100.0) 17 (100.0) 31 (100.0) 32 (100.0) 47 (100.0) 137 (100.0)
6¼Fisher’s exact test
doi:10.1371/journal.pone.0127495.t001
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Table 2. Associations between discrepancies and timing of registration, type of sponsorship, and presence of significant results.
Discrepancy between registry and publication for the
primary outcome
p-value
Yes No Not reported Total
N (%) N (%) N (%) N (%)
Timing of registration 0.11*
Prospective 20 (80.0) 102 (91.1) - 122 (89.0)
Retrospective 5 (20.0) 10 (8.9) - 15 (11.0)
Funding Source 0.926¼
Government/university 17 (68.0) 68 (60.7) - 85 (62.0)
Company/corporation 8 (32.0) 40 (35.7) - 48 (35.0)
None/not reported 0 (0.0) 1 (0.9) - 1 (0.7)
Both 0 (0.0) 3 (2.7) - 3 (2.3)
Signiﬁcance of Primary Outcome 0.92*
Non-signiﬁcant 13 (52.0) 57 (50.9) - 70 (51.1)
Signiﬁcant 12 (48.0) 55 (49.1) - 67 (48.9)
Total 25 (100.0) 112 (100.0) - 137 (100.0)
Discrepancy between registry and publication for the
non-primary outcome
Timing of registration 0.39*
Prospective 79 (90.8) 43 (86.0) - 122 (89.1)
Retrospective 8 (9.2) 7 (14.0) - 15 (10.9)
Funding Source 0.206¼
Government/university 51 (58.6) 34 (68.0) - 85 (62.0)
Company/corporation 33 (37.9) 15 (30.0) - 48 (35.0)
None/not reported 0 (0.0) 1 (2.0) - 1 (0.8)
Both 3 (3.5) 0 (0.0) - 3 (2.2)
Signiﬁcance of Primary Outcome 0.58*
Non-signiﬁcant 46 (52.9) 24 (48.0) - 70 (51.1)
Signiﬁcant 41 (47.1) 26 (52.0) - 67 (48.9)
Total 87 (100.0) 50 (100.0) 137 (100)
Primary outcome in registry omitted from publication
Timing of registration 0.996¼
Prospective 8 (88.9) 114 (89.1) - 122 (89.1)
Retrospective 1 (11.1) 14 (10.9) - 15 (10.9)
Funding Source 0.796¼
Government/university 5 (55.6) 80 (62.5) - 85 (62)
Company/corporation 4 (44.4) 44 (34.4) - 48 (35.1)
None/not reported 0 (0.0) 1 (0.8) - 1 (0.7)
Both 0 (0.0) 3 (2.3) - 3 (2.2)
Signiﬁcance of Primary Outcome 0.996¼
Non-signiﬁcant 5 (55.6) 65 (50.8) - 70 (51.1)
Signiﬁcant 4 (44.4) 63 (49.2) - 67 (48.9)
Total 9 (100.0) 128 (100.0) 100 (137)
Non-primary outcome in registry omitted from
publication
Timing of registration 0.54*
Prospective 47 (87.0) 75 (90.4) - 122 (89.1)
Retrospective 7 (13.0) 8 (9.6) - 15 (10.9)
(Continued)
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identified for surgical journals [6]; however, even higher levels (70%) have been exposed [7].
The most pervasive issues in the present report related to either omission (39%) or de novo in-
troduction (44%) of non-primary outcomes in the published reports. Upgrade of non-primary
outcomes to primary was relatively rare (2%); this figure corresponds with previous research
alluding to a rate of 3% for this discrepancy [7], although levels of up to 14% have been re-
ported [6]. No association was found between discrepancies in outcome reporting and statisti-
cal significance of the results. This finding may reflect a lack of power to identify a true
difference. It may, however, be possible that outcomes are changed within clinical trials follow-
ing genuine post hoc decisions, for example, based on pilot studies, recruitment or due to advice
from data monitoring committees. Notwithstanding this, it is important that post hoc changes
of this nature are delineated within the published manuscript, ideally accompanied by an ex-
planation of the reasons for the change.
In respect of sample size, a discrepancy was found in 45% of trials. This figure is in general
keeping with previous studies, which have alluded to differences in the region of 48% to 73% of
entries [6, 17]. The veracity of the sample size calculations and the information contributing to
the calculated values were not assessed in the present study; however, previous research has ex-
posed problems in this respect [18, 19]. Consequently, further efforts are required both in
Table 2. (Continued)
Discrepancy between registry and publication for the
primary outcome
p-value
Yes No Not reported Total
N (%) N (%) N (%) N (%)
Funding Source 0.536¼
Government/university 36 (66.7) 49 (59) - 85 (62)
Company/corporation 18 (33.3) 30 (36.2) - 48 (35.1)
None/not reported 0 (0.0) 1 (1.2) - 1 (0.7)
Both 0 (0.0) 3 (3.6) - 3 (2.2)
Signiﬁcance of Primary Outcome 0.89*
Non-signiﬁcant 28 (51.9) 42 (50.6) - 70 (51.1)
Signiﬁcant 26 (48.1) 41 (49.4) - 67 (48.9)
Total 54 (100.0) 83 (100.0) 137 (100.0)
Discrepancy between registry and publication for the
inclusion criteria
Timing of registration 0.996¼
Prospective 30 (90.9) 91 (88.3) 1 (100.0) 122 (89.1)
Retrospective 3 (9.1) 12 (11.7) 0 (0.0) 15 (10.9)
Funding Source 0.0146¼
Government/university 14 (42.4) 71 (68.9) 0 (0.0) 85 (62.1)
Company/corporation 17 (51.5) 30 (29.1) 1 (100.0) 48 (35)
None/not reported 0 (0.0) 1 (1.0) 0 (0.0) 1 (0.7)
Both 2 (6.1) 1 (1.0) 0 (0.0) 3 (2.2)
Signiﬁcance of Primary Outcome 0.776¼
Non-signiﬁcant 16 (48.9) 54 (52.4) 0 (0.0) 70 (51.1)
Signiﬁcant 17 (51.5) 49 (47.6) 1 (100.0) 67 (48.9)
Total 33 (100.0) 103 (100.0) 1 (100.0) 137 (100.0)
*chi-square,
6¼Fisher’s exact test
doi:10.1371/journal.pone.0127495.t002
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relation to the clarity and conduct of sample size estimation in clinical trials. It is particularly
important, however, that sample size estimation is delineated in trial reports due to the risk of
biased post hoc decisions in an effort to demonstrate that clinical trials possessed the requisite
power to demonstrate clinically relevant differences where they are identified [20].
A number of factors described in the final report were rarely delineated in the registry entry.
Subgroup analyses were referred to in only 6% of registry entries, while analyses were reported
in the final paper in 54% without previous mention in the register. Similarly, randomization
procedures, ethical approval status (74%) and mode of population analysis (88%) were rarely
outlined in registry entries. This pattern may be overcome by stipulating mandatory entries in
relation to each of these areas on trial registers or by providing additional space to provide fur-
ther relevant but non-essential information. It has been demonstrated that completion of man-
datory components is almost universal on recognized databases (e.g. ClinicalTrials.gov) [21],
while optional fields are completed with significantly lower frequency. Completion rates were
just 66% and 56%, respectively, for primary and non-primary outcomes. While evidence point-
ing to improved outcomes favoring sponsors of published pharmaceutical studies and a recog-
nized susceptibility to publication bias exists [22], in the present study no association between
either primary or non-primary outcome change or omission and either registration timing or
source of funding was found.
Despite the adoption, promotion and endorsement of reporting guidelines, there remain
significant shortcomings [2]. The emphasis should, therefore, shift to implementing changes
rather than allowing relatively passive submission, peer review and editorial consideration,
while expecting improvements in reporting and conduct. While stipulation of mandatory ele-
ments on registry databases is effective, it may be possible to implement a registry modeled on
CONSORT items completed prospectively to stimulate optimal trial design and clarity at the
protocol stage. The Standard Protocol Items: Recommendations for Intervention (SPIRIT)
checklist has recently been developed with the intention of clarifying the items required during
protocol reporting. Within these 33 items relating to all aspects of trial design, including ethics
and dissemination are mentioned [23]. If the SPIRIT guidelines become embraced as a stan-
dard technique for outlining protocols of clinical trials, it is likely that these omissions will be
rectified, particularly if registry entries could be made to reflect more detailed protocols rather
than being restricted to more limited fields. Biomedical journals are beginning to adopt the
SPIRIT statement and as acceptance increases it is possible trial registries may be modeled
more closely on SPIRIT guidance [24]. A further option might be to append the registry entry
to final submissions for inspection during the peer review process with authors encouraged to
outline discrepancies between them to promote greater clarity and candor.
Limitations of this study include its restriction to a six-month period and to a subset of just
five journals. These journals were included as they are prominent, well regarded and have the
highest impact factors. It was therefore hoped that these might represent best practice with
more significant discrepancies arising in less prominent journals. While the latter appears to
apply to methodological quality of both systematic reviews and RCTs, there is no conclusive
evidence that this extends to selective outcome reporting [14, 15]. It would be intuitive to ex-
pect, however, that journals not stipulating the need for trial registration are likely to present
similar or higher rates of discrepancy. Moreover, registry entries do not at this stage correspond
to trial protocols as protocols are not usually publically available. It is possible, therefore, that
information on registries was truncated deliberately in an effort to comply with registry poli-
cies. The benefit of encouraging more complete registry entries, with an onus on mandatory
completion is, therefore, clear. Finally, it had been hoped to investigate the association between
selective reporting and observed estimates; this was not possible due to the relatively low num-
ber of studies examined. It may be interesting, however, to investigate whether selective
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reporting of trial outcomes is associated with distortion of effect estimates likely resulting in a
greater preponderance of positive outcomes for de novo primary or non-primary outcomes,
which were not outlined in the registry.
Conclusions
A high rate of discrepancies between registry entries and published articles for primary and
non-primary outcomes were identified among a sample of trials published in leading medical
journals. Selective outcome reporting, therefore, appears to be a persistent issue. Novel ap-
proaches are required to address this issue throughout biomedical research.
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